Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 2015, with a specific report date of April 13, 2015. The document serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMRs) in compliance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to disclosure of shareholding changes and does not contain financial performance data.
Material Changes
The filing reports increases in the notional interests of seven PDMRs in GSK Ordinary Shares. These increases resulted from the re-investment of dividends paid on shares held in the GlaxoSmithKline Deferred Investment Award Programme. The transactions occurred at a price of 1606.50 pence per Share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory notification of director share transactions.
Important Facts for Investors
- Transaction Type: Increases in notional share interests via dividend re-investment.
- Share Price: Transactions executed at 1606.50 pence per Ordinary Share.
- Participants: Mr R G Connor, Mr S A Hussain, Mr D S Redfern, Ms C Thomas, Dr P J T Vallance, Ms E Walmsley, and Mrs V A Whyte.
- Share Quantities: Increases ranged from 115.049 shares (Mrs V A Whyte) to 941.862 shares (Ms E Walmsley).
- Signatory: Victoria Whyte, Company Secretary, signed the report on behalf of the registrant.